Aclaris Therapeutics Inc (ACRS) concluded trading on Wednesday at a closing price of $1.32, with 3.53 million shares of worth about $4.65 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 13.79% during that period and on July 17, 2024 the price saw a loss of about -1.49%. Currently the company’s common shares owned by public are about 70.89M shares, out of which, 65.48M shares are available for trading.
Stock saw a price change of 3.94% in past 5 days and over the past one month there was a price change of 11.86%. Year-to-date (YTD), ACRS shares are showing a performance of 25.71% which decreased to -87.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.59 but also hit the highest price of $11.12 during that period. The average intraday trading volume for Aclaris Therapeutics Inc shares is 879.73K. The stock is currently trading 9.29% above its 20-day simple moving average (SMA20), while that difference is up 12.86% for SMA50 and it goes to -27.92% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aclaris Therapeutics Inc (NASDAQ: ACRS) currently have 70.89M outstanding shares and institutions hold larger chunk of about 76.65% of that.
The stock has a current market capitalization of $94.06M and its 3Y-monthly beta is at 0.31. It has posted earnings per share of -$1.09 in the same period. It has Quick Ratio of 6.74 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ACRS, volatility over the week remained 5.43% while standing at 7.10% over the month.
Stock’s fiscal year EPS is expected to rise by 37.07% while it is estimated to increase by 21.28% in next year.
On October 03, 2023, Evercore ISI Initiated their recommendations, while on December 14, 2022, Stifel Initiated their ratings for the stock with a price target of $29. Stock get a Buy rating from Goldman on December 01, 2022.
